Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.

Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.
Curr Opin Immunol. 2017 Jul 24;47:78-84
Authors: Izzo AA
Abstract
The development of novel vaccine candidates against infections with Mycobacterium tuberculosis has highlighted our limited understanding of immune mechanisms required to kill M. tuberculosis. The induction of a Th1 immunity is vital, but new studies are required to identify other mechanisms that may be necessary. Novel vaccines formulations that invoke effector cells such as innate lymphoid cells may provide an environment that promote effector mechanisms including T cell and B cell mediated immunity. Identifying pathways associated with killing this highly successful infectious agent has become critical to achieving the goal of reducing the global tuberculosis burden.
PMID: 28750280 [PubMed - as supplied by publisher]

Source: Current Opinion in Immunology - July 24, 2017 Category: Allergy & Immunology Authors: Izzo AA Tags: Curr Opin Immunol Source Type: research